1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELeu-AMSCat. No.: HY-108900CAS No.: 288591-93-5分式: CHNOS分量: 459.48作靶點(diǎn): Bacterial; Aminoacyl-tRNA Synthetase作通路: Anti-infection; Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體

2、外實(shí)驗(yàn) DMSO : 49.17 mg/mL (107.01 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.1764 mL 10.8819 mL 21.7637 mL5 mM 0.4353 mL 2.1764 mL 4.3527 mL10 mM 0.2176 mL 1.0882 mL 2.1764 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Leu-AMS亮

3、氨酰-tRNA 合成酶 (LRS) 的有效抑制劑，其 IC50 值為 22.34 nM 且能夠抑制細(xì) 的長(zhǎng)。IC50 & Target IC50: 22.34 nM (LRS) 1體外研究Leu-AMS is proved to be a potent inhibitor of Leucyl-tRNA Synthetase (LRS) with an IC50 value of 22.34 nM.Leu-AMS is highly cytotoxic in both cancer cells and normal cells. Leu-AMS does not affect S6 kinase

4、 (S6K)1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEphosphorylation at all. Leu-AMS inhibits the catalytic activity of LRS but does not affect the leucine-inducedmTORC1 activation 1.REFERENCES1. Yoon S, et al. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-TargetedMammalian Target ofRapamycin Complex 1 (mTORC1) Inhibitors. J Med Chem. 2016 Nov 23;59(22):10322-10328.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;